This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Trulicity
  • /
  • A Study of Dulaglutide (LY2189265) in Participants...
Clinical trial

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Read time: 1 mins
Last updated:1st Nov 2015

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Estimated Enrollment: 357
Study Start Date: November 2015
Estimated Study Completion Date: May 2017
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)

- Experimental: 0
.75 mg dulaglutide
- Experimental: 1.5 mg dulaglutide
- Placebo Comparator: Placebo

Category Value
Study start date 2015-11-01

View full details